Tranilast, an orally active antiallergic compound, inhibits extracellular matrix production in human uterine leiomyoma and myometrial cells.
about
Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growthSignaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for TherapyVersican Proteolysis by ADAMTS Proteases and Its Influence on Sex Steroid Receptor Expression in Uterine Leiomyoma.Tranilast Inhibits Genes Functionally Involved in Cell Proliferation, Fibrosis, and Epigenetic Regulation and Epigenetically Induces miR-29c Expression in Leiomyoma Cells.
P2860
Tranilast, an orally active antiallergic compound, inhibits extracellular matrix production in human uterine leiomyoma and myometrial cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Tranilast, an orally active an ...... eiomyoma and myometrial cells.
@en
type
label
Tranilast, an orally active an ...... eiomyoma and myometrial cells.
@en
prefLabel
Tranilast, an orally active an ...... eiomyoma and myometrial cells.
@en
P2093
P1476
Tranilast, an orally active an ...... eiomyoma and myometrial cells.
@en
P2093
Andrea Ciavattini
Andrea Luigi Tranquilli
Mario Castellucci
Olga Protic
Stefano Raffaele Giannubilo
William H Catherino
P304
P356
10.1016/J.FERTNSTERT.2014.05.013
P407
P577
2014-06-14T00:00:00Z